{"product_id":"organon-five-forces-analysis","title":"Organon Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eA Must-Have Tool for Decision-Makers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cporganon porter five forces snapshot highlights moderate supplier power evolving buyer dynamics regulatory barriers manageable threat of substitutes and intense rivalry in branded specialty segments.\u003e\u003cpthis brief snapshot only scratches the surface. unlock full porter five forces analysis to explore organon competitive dynamics market pressures and strategic advantages in detail.\u003e\n\u003c\/pthis\u003e\u003c\/porganon\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized API Procurement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrganon depends on a complex supplier network for active pharmaceutical ingredients (APIs) across women’s health and legacy brands; scarcity of high-quality precursors for hormonal drugs gives those specialized suppliers strong pricing leverage. By end-2025 Organon had diversified sourcing—cut single-source suppliers by ~30%—which helped cap API cost inflation to ~4% year-over-year despite global raw-material inflation of ~8%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiologic Manufacturing Requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe production of biosimilars needs specialized bioreactors, single‑use systems, and process analytics supplied by a handful of global vendors, creating high switching costs and supplier power; about 70% of biologics COGS relates to these inputs. Organon reduces risk via multi‑year supply agreements and strategic partnerships for media and reagents, locking prices and capacity and cutting disruption risk for high‑margin biosimilars that can represent \u0026gt;20% of portfolio gross margin.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePost-Spin-Off Service Agreements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSince the 2021 spin-off from Merck, Organon relied on transition service agreements (TSAs) for manufacturing, which ensured supply but constrained price negotiations and raised COGS by an estimated 3–5 percentage points in 2022–23.\u003c\/p\u003e\n\u003cp\u003eBy late 2025 Organon reports internalizing ~60% of former TSA volumes and contracting new third-party manufacturers, trimming manufacturing spend by roughly $120–150 million annually versus staying under TSAs.\u003c\/p\u003e\n\u003cp\u003eThis operational independence strengthened Organon’s leverage with legacy suppliers, lowering supplier bargaining power and improving gross margin resilience; supplier dependence now centers on specialized biologics inputs where switching costs remain moderate.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance Standards\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSuppliers must meet strict Good Manufacturing Practices and international standards (FDA, EMA), creating a small pool of qualified vendors and raising their bargaining power for Organon.\u003c\/p\u003e\n\u003cp\u003eOrganon runs frequent supplier audits; in 2024 it reported 18% of global suppliers reviewed annually to avoid recalls and regulatory delays that can cost millions per incident.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSmall qualified supplier pool increases leverage\u003c\/li\u003e\n\u003cli\u003eGMP\/FDA\/EMA compliance is mandatory\u003c\/li\u003e\n\u003cli\u003eOrganon audits ~18% suppliers yearly (2024)\u003c\/li\u003e\n\u003cli\u003eNoncompliance risk: multi-million USD recalls\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLogistics and Cold Chain Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSpecialized logistics and cold chain providers hold moderate bargaining power due to high capital needs for biologics-grade temperature control; Organon offsets this by using competitive global bids that in 2024–2025 drove shipping cost savings of about 6–8% versus prior contracts.\u003c\/p\u003e\n\u003cp\u003eBy late 2025 Organon deployed advanced end-to-end GPS and IoT tracking across 95% of temperature-sensitive shipments, improving on-time integrity checks from 91% to 98% year-over-year.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eModerate supplier power: high infrastructure barriers\u003c\/li\u003e\n\u003cli\u003eCompetitive bidding saved ~6–8% in shipping\u003c\/li\u003e\n\u003cli\u003e95% coverage with IoT\/GPS by late 2025\u003c\/li\u003e\n\u003cli\u003eIntegrity checks improved 91% → 98%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrganon trims single-source exposure 30%, saves $120–150M, boosts IoT to 95%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrganon faces moderate supplier power: specialized API and biologics-input vendors command premiums, but diversification and internalizing former TSAs cut single-source suppliers ~30% and saved $120–150m annually by late 2025; shipping bids cut logistics costs 6–8% and IoT coverage rose to 95%, lifting integrity checks 91%→98%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSingle-source suppliers cut\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual savings from internalization\u003c\/td\u003e\n\u003ctd\u003e$120–150m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLogistics cost reduction (2024–25)\u003c\/td\u003e\n\u003ctd\u003e6–8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIoT\/GPS coverage\u003c\/td\u003e\n\u003ctd\u003e95%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntegrity checks\u003c\/td\u003e\n\u003ctd\u003e91% → 98%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter's Five Forces analysis for Organon that uncovers key drivers of competition, buyer and supplier power, entry barriers, substitutes, and disruptive threats, with strategic commentary and industry data to inform pricing, profitability, and defensive moves.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eClear, one-sheet Porter's Five Forces for Organon—instantly pinpoint competitive pressures and strategic levers to relieve pain points in pricing, R\u0026amp;D prioritization, and market entry decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWholesale Distributor Concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpa large portion of organon revenue comes from a few wholesalers amerisourcebergen and cardinal health together bought roughly u.s. pharma volumes in giving them strong bargaining power due to scale.\u003e\n\u003cporganon must protect distribution access by keeping deep commercial ties and concessionary contracts securing preferred placement often pressures margins when negotiating rebates fees payment terms.\u003e\n\u003c\/porganon\u003e\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Health Systems and Tenders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn many markets government-funded health systems use centralized tenders to cut drug costs; public payers can push prices down by 20–60% versus list prices, giving them strong leverage over Organon.\u003c\/p\u003e\n\u003cp\u003eFor established brands and biosimilars with multiple suppliers, payers can demand steep discounts, so Organon must show cost-effectiveness and therapeutic value to win high-volume EU and emerging-market contracts.\u003c\/p\u003e\n\u003cp\u003eMissing inclusion on a national formulary often causes sales to fall sharply; studies show exclusion can reduce market share by 30–70% within 12 months, so tender losses materially hit revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmacy Benefit Managers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn the US, Pharmacy Benefit Managers (PBMs) decide coverage and tiers, using 2024 median rebate rates near 40% to extract deep discounts from manufacturers like Organon.\u003c\/p\u003e\n\u003cp\u003ePBMs’ leverage over Organon affects formulary placement for women's health products, directly shaping patient access and sales growth; a single preferred tier can lift uptake by 15–25%.\u003c\/p\u003e\n\u003cp\u003eBy 2025 Organon prioritizes robust real-world and claims data to justify prices to PBMs, citing internal outcomes studies and a 2023‑24 payer win rate improvement of about 8%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital Group Purchasing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHospital systems use Group Purchasing Organizations (GPOs) to secure bulk discounts; in 2024 GPOs covered ~80% of US hospital procurement, boosting buyer leverage against suppliers like Organon.\u003c\/p\u003e\n\u003cp\u003eGPOs can redirect demand to lower-cost biosimilars; Organon counters by stressing proven clinical reliability, 24\/7 supply-chain support, and contract terms to protect margins.\u003c\/p\u003e\n\u003cp\u003eMaintaining on-time fill rates (\u0026gt;98%), strong pharmacovigilance, and volume-based rebates is critical for winning GPO-preferred status.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGPO coverage ~80% of US hospitals (2024)\u003c\/li\u003e\n\u003cli\u003eOn-time fill \u0026gt;98% target\u003c\/li\u003e\n\u003cli\u003eUse clinical data + support to defend price\u003c\/li\u003e\n\u003cli\u003eVolume rebates and supply guarantees matter most\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Influence and Advocacy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePatient advocacy groups and rising health literacy mean consumers increasingly influence prescriptions and stocking for women’s health, with 52% of US women reporting they asked providers for specific contraceptives in a 2024 survey.\u003c\/p\u003e\n\u003cp\u003eOrganon runs disease-awareness and education campaigns—spending about $120m on marketing in 2024—to build direct brand loyalty and drive demand for products like long-acting reversible contraceptives.\u003c\/p\u003e\n\u003cp\u003eThis pull strategy reduces price sensitivity from hospitals and pharmacies by creating organic patient-driven demand, helping protect margins against institutional buyer pressure.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e52% of US women requested specific contraceptives (2024 survey)\u003c\/li\u003e\n\u003cli\u003eOrganon marketing ~ $120m (2024)\u003c\/li\u003e\n\u003cli\u003ePatient-driven demand lowers institutional price pressure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrganon fights powerful buyers with data, supply guarantees, rebates \u0026amp; $120M marketing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cporganon faces high customer bargaining power: top three wholesalers bought of u.s. pharma volumes pbms drove median rebates gpos covered hospital procurement and tender exclusions can cut market share within months organon counters with real-world data supply guarantees\u003e98% fill targets, volume rebates, and $120m marketing (2024).\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop-3 wholesaler share\u003c\/td\u003e\n\u003ctd\u003e60–70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBM median rebate\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGPO hospital coverage\u003c\/td\u003e\n\u003ctd\u003e~80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFormulary exclusion impact\u003c\/td\u003e\n\u003ctd\u003e30–70% loss\/12m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn-time fill target\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;98%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarketing spend\u003c\/td\u003e\n\u003ctd\u003e$120m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/porganon\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eOrganon Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Organon Porter’s Five Forces analysis you'll receive immediately after purchase—no placeholders or samples; fully formatted and ready for download. The document is the complete, professionally written deliverable, covering competitive rivalry, supplier and buyer power, threat of substitutes, and barriers to entry with actionable insights. Purchase grants instant access to this identical file for immediate use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747317068153,"sku":"organon-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/organon-five-forces-analysis.png?v=1772197498","url":"https:\/\/matrixbcg.com\/products\/organon-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}